Yanquan Zhang

Yanquan Zhang

Auto-generated profile, based on publicly available information

Yanquan Zhang

Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
DLDabin Liu
Dabin Liu
CWChi Chun Wong
Chi Chun Wong
LFLi Fu
Li Fu
HCHuarong Chen
Huarong Chen
LZLiuyang Zhao
Liuyang Zhao
JYJun Yu
Jun Yu
Nonalcoholic fatty liver disease (NAFLD)–induced hepatocellular carcinoma (HCC) is an emerging malignancy in the developed world; however, mechanisms that contribute to its formation are largely unknown, and targeted therapy is currently not available. Our RNA sequencing analysis of NAFLD-HCC samples revealed squalene epoxidase (SQLE) as the top outlier metabolic gene overexpressed in NAFLD-HCC patients. Hepatocyte-specific Sqle transgenic expression in mice accelerated the development of high-fat, high-cholesterol diet–induced HCC. SQLE exerts its oncogenic effect via its metabolites, cholesteryl ester and nicotinamide adenine dinucleotide phosphate (NADP+). Increased SQLE expression promotes the biosynthesis of cholesteryl ester, which induces NAFLD-HCC cell growth. SQLE increased the NADP+/NADPH (reduced form of NADP+) ratio, which triggered a cascade of events involving oxidative stress–induced DNA methyltransferase 3A (DNMT3A) expression, DNMT3A-mediated epigenetic silencing of PTEN, and activation of AKT-mTOR (mammalian target of rapamycin). In human NAFLD-HCC and HCC, SQLE is overexpressed and its expression is associated with poor patient outcomes. Terbinafine, a U.S. Food and Drug Administration–approved antifungal drug targeting SQLE, markedly inhibited SQLE-induced NAFLD-HCC cell growth in NAFLD-HCC and HCC cells and attenuated tumor development in xenograft models and in Sqle transgenic mice. Suppression of tumor growth by terbinafine is associated with decreased cholesteryl ester concentrations, restoration of PTEN expression, and inhibition of AKT-mTOR, consistent with blockade of SQLE function. Collectively, we established SQLE as an oncogene in NAFLD-HCC and propose that repurposing SQLE inhibitors may be a promising approach for the prevention and treatment of NAFLD-HCC.

1 January 2012 in Cancer Cell
Verified
Journal Article
Closed access
DLDongdong Lu
Dongdong Lu
YWYinyuan Wu
Yinyuan Wu
YWYinyin Wang
Yinyin Wang
FRFangli Ren
Fangli Ren
DWDianjun Wang
Dianjun Wang
ZCZhijie Chang
Zhijie Chang

1 September 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YKYifan Kong
Yifan Kong
LCLijun Cheng
Lijun Cheng
FMFengyi Mao
Fengyi Mao
ZZZhuangzhuang Zhang
Zhuangzhuang Zhang
YZYanquan Zhang
Yanquan Zhang
XLXiaoqi Liu
Xiaoqi Liu
Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved for the management of castration-resistant prostate cancer (CRPC). Although patients can benefit from enzalutamide at the beginning of this therapy, acquired enzalutamide resistance usually occurs within a short period. This motivated us to investigate the mechanism involved and possible approaches for overcoming enzalutamide resistance in CRPC. In the present study, we found that HMG-CoA reductase (HMGCR), a crucial enzyme in the mevalonate pathway for sterol biosynthesis, is elevated in enzalutamide-resistant prostate cancer cell lines. HMGCR knockdown could re-sensitize these cells to the drug, and HMGCR overexpression conferred resistance to it, suggesting that aberrant HMGCR expression is an important enzalutamide resistance mechanism in prostate cancer cells. Furthermore, enzalutamide-resistant prostate cancer cells were more sensitive to statins, which are HMGCR inhibitors. Of note, a combination of simvastatin and enzalutamide significantly inhibited the growth of enzalutamide-resistant prostate cancer cells in vitro and tumors in vivo. Mechanistically, simvastatin decreased protein levels of the androgen receptor (AR), which was further reduced in combination with enzalutamide. We observed that the decrease in AR may occur through simvastatin-mediated inhibition of the mTOR pathway, whose activation was associated with increased HMGCR and AR expression. These results indicate that simvastatin enhances the efficacy of enzalutamide-based therapy, highlighting the therapeutic potential of statins to overcome enzalutamide resistance in CRPC.

8 August 2011 in Asian Journal of Andrology
Verified
Journal Article
Open access
WLWei-Ren Li
Wei-Ren Li
LCLiang Chen
Liang Chen
ZCZhi-Jie Chang
Zhi-Jie Chang
HXHua Xin
Hua Xin
TLTao Liu
Tao Liu
ZXZhongcheng Xin
Zhongcheng Xin
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.

1 January 2017 in Theranostics
Verified
Journal Article
Open access
JDJinghua Du
Jinghua Du
XZXiang Zhang
Xiang Zhang
JHJuqiang Han
Juqiang Han
KMKwan Man
Kwan Man
YZYanquan Zhang
Yanquan Zhang
JYJun Yu
Jun Yu
Mitochondrial dysfunction plays a crucial role in the development of non-alcoholic steatohepatitis (NASH). However, the regulator of mitochondrial dysfunction in the pathogenesis of NASH is still largely unclear. CXCR3 is an essential pro-inflammatory factor in chronic liver diseases. We explored the significance of CXCR3 in regulating mitochondrial function during NASH development in animal models and cultured hepatocytes.

27 March 2017 in Oncogene
Verified
Journal Article
Closed access
PDF file
YSY Shang
Y Shang
JHJ He
J He
YWY Wang
Y Wang
QFQ Feng
Q Feng
YZY Zhang
Y Zhang
ZCZ Chang
Z Chang